If abiraterone becomes the standard care will there be cost implications_

Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses cost implications when abiraterone becomes standard care for prostate cancer treatment. This was recorded at the 2017 ASCO... Author: obr Added: 06/23/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts